Diagnostic accuracy and safety of 16α-[18F]fluoro-17β-oestradiol PET-CT for the assessment of oestrogen receptor status in recurrent or metastatic lesions in patients with breast cancer: a prospective cohort study.

MLA

Chae, Sun Young, et al. “Diagnostic Accuracy and Safety of 16α-[18F]Fluoro-17β-Oestradiol PET-CT for the Assessment of Oestrogen Receptor Status in Recurrent or Metastatic Lesions in Patients with Breast Cancer: A Prospective Cohort Study.” Lancet Oncology, vol. 20, no. 4, Apr. 2019, pp. 546–55. EBSCOhost, https://doi.org/10.1016/S1470-2045(18)30936-7.

APA

Chae, S. Y., Ahn, S. H., Kim, S.-B., Han, S., Lee, S. H., Oh, S. J., Lee, S. J., Kim, H. J., Ko, B. S., Lee, J. W., Son, B. H., Kim, J., Ahn, J.-H., Jung, K. H., Kim, J. E., Kim, S.-Y., Choi, W. J., Shin, H. J., Gong, G., & Lee, H. S. (2019). Diagnostic accuracy and safety of 16α-[18F]fluoro-17β-oestradiol PET-CT for the assessment of oestrogen receptor status in recurrent or metastatic lesions in patients with breast cancer: a prospective cohort study. Lancet Oncology, 20(4), 546–555. https://doi.org/10.1016/S1470-2045(18)30936-7

Chicago

Chae, Sun Young, Sei Hyun Ahn, Sung-Bae Kim, Sangwon Han, Suk Hyun Lee, Seung Jun Oh, Sang Ju Lee, et al. 2019. “Diagnostic Accuracy and Safety of 16α-[18F]Fluoro-17β-Oestradiol PET-CT for the Assessment of Oestrogen Receptor Status in Recurrent or Metastatic Lesions in Patients with Breast Cancer: A Prospective Cohort Study.” Lancet Oncology 20 (4): 546–55. doi:10.1016/S1470-2045(18)30936-7.